Market Growth Outlook Summary
The global AMD drugs market growth forecasted to transform from $10.46 billion in 2024 to $17.37 billion by 2029, driven by a CAGR of 10.7%. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
Browse in-depth TOC on "Age-related Macular Degeneration (AMD) Drugs Market
378 - Tables
54 - Figures
336 – Pages
Eylea accounted for the largest share of the product segment in the Age-Related Macular Degeneration (AMD) drugs market
Based on products, the Age-Related Macular Degeneration (AMD) drugs market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Others (including Izervay, Beovu, Conbercept, Byooviz, among others). In 2023, Eylea & Eylea HD accounted for the largest share of the Age-Related Macular Degeneration (AMD) drugs market. This large share of this AMD drug can be attributed to the high rate of adoption among patients. Various studies have shown that this drug is the preferred choice of treatment for wet AMD by many ophthalmologists. The drug is also approved for various other retinal disorders such as Retinal Vein Occlusion (RVO) and Diabetic Macular Edema, among others.
The wet AMD disease type accounted for the largest share of the type of AMD segment in the Age-Related Macular Degeneration (AMD) drugs market
Based on the type of AMD, the Age-Related Macular Degeneration (AMD) drugs market is segmented into wet AMD and dry AMD. The wet AMD segment accounted for the largest share of the AMD drugs market in 2023 owing to the high prevalence of the disease affecting approximately 20 million individuals globally and most of the drugs in the AMD market such as Eylea & Eylea HD, Vabysmo, Lucentis, Byooviz, and Cimerli among others are developed for the treatment of this disease. The prevalence of this disease is increasing due to the rise in the geriatric population across the globe, with the World Health Organization (WHO) predicting the number of individuals above 60 years of age to double by 2050.
North America was the largest regional market for Age-Related Macular Degeneration (AMD) therapies
Based on geography, the Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America accounted for the largest share of the Age-Related Macular Degeneration (AMD) drugs market, followed by Europe and the Asia Pacific. The large share of the North American Age-Related Macular Degeneration (AMD) drug market can be attributed to factors such as the rising prevalence of AMD cases in the US leading to a rise in the health care spending in the region. The increase in the approvals of AMD drugs in the regions also supports the large share of the market, with major drug-developing companies conducting clinical trials in the US for the approval of their pipeline drugs.
The prominent players in the global Age-Related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China) and Sandoz Group AG (Switzerland). The market also includes players, such as Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited (Australia), Kodiak Sciences Inc. (US), Innovent (China), Bio-Thera Solution (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China), and Adverum Biotechnologies, Inc. (US), that have drug candidates in phase 3 clinical trials.
Regeneron Pharmaceuticals Inc. (US):
Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD). Eylea is one of the most adopted therapeutic drugs for the treatment of wet AMD across the globe. The company has partnered with major pharmaceutical companies such as Bayer AG to manufacture and distribute the drugs outside the US. Regeneron has operations in over 12 countries across the Asia Pacific, Europe, and North America, and conducts clinical trials in more than 60 countries. In 2023, the company allocated USD 96.2 million to improve Eylea HD, a higher hose of its already successful AMD drug Eylea. This drug allows patients to obtain similar therapeutic results with less number of injections reducing the treatment burden on the patients. The company has also developed innovative technologies like TRAPS and VelociSuite, which are used for the development of bispecific antibodies, essential for the development of next-generation ophthalmic drugs.
F. Hoffmann-La Roche Ltd (Switzerland):
Roche is a major pharmaceutical company that offers three FDA-approved drugs for the treatment of wet AMD among other retinal diseases: Lucentis, Vabysmo, and Susvimo, the company also provides Avastin (Bevacizumab) which is widely used as an off-label drug for the treatment of wet AMD owing to its affordability. In 2023, the company invested approximately 22% (USD 14.7 billion) of its annual revenue in R&D for the development of new drugs and exploring advanced research methods, including computational biology. The company has received marketing approvals for its AMD drugs in many countries, with recent expansions into markets like India. Roche's Genentech Ophthalmology Co-pay Program helps cover drug and administration costs making treatments more affordable. The company has operations in over 95 countries and offers a wide range of therapeutic products for a variety of diseases and disorders.
Novartis AG (Switzerland):
Novartis AG is a biotechnology company that focuses on the development and distribution of innovative medicines across key therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, ophthalmology, and oncology. In 2023, Novartis became a pure-play innovative medicines company by spinning off its Sandoz generic and biosimilar business unit. The company strongly focuses on ophthalmology, and markets FDA-approved drugs like Lucentis and Beovu (brolucizumab) for treating wet Age-Related Macular Degeneration (AMD) across the globe. Novartis is also conducting phase 3 clinical trials for Beovu to expand its use for diabetic retinopathy, highlighting the company's focus on innovation and expanding treatment options. The company operates in over 130 countries and uses contract structures such as pay-over-time and outcome-based agreements to make its products more affordable and accessible to patients.
For more information, Inquire Now!
Content Source:
https://www.marketsandmarkets.com/ResearchInsight/age-related-macular-degeneration-market.asp
https://www.marketsandmarkets.com/PressReleases/age-related-macular-degeneration.asp
Comments
0 comment